Mr Kempler has been Chairman of Alterity Therapeutics Limited (ASX:ATH) Board of Directors since 1997 and served as a Chairman and Non-Executive Director of Opthea Limited, an ASX and NASDAQ listed drug development company, from November 2015 until October 2020. He was appointed Chairman of Ausbiotech, Australia’s biotechnology organization, in November 2021. Mr. Kempler is one of the founders of Alterity Therapeutics Limited.
Latest News
Wilsons Updated Research Report
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
ShareCafe Webinar 29 April 2022
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed its phase II clinical trial, including when the company is expecting results from the trial. This...
NailMail Q1 2022
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include: Appointed Mr Philip Rose as Chief Commercial Officer and strengthened the manufacturing team with the appointment of Mr Om...